uniQure N.V. (QURE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

uniQure N.V.

NasdaqGS•Healthcare•Biotechnology

$42.49-0.61(-0.01%)Pre-market

Market Cap

$2.92B

P/S

156.4x

P/B

9.0x

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

How this company scores

WeakMetricSide Score: 47/100

Grade capped at D — Interest coverage below 1× (-3.5x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (8/25).

Profitability11/25

Growth13/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueLong cash runwayLow leverageNet cash position

Grade capped at D

Interest coverage below 1× (-3.5x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 2.6x5y range 2.6x – 4.5x

P/S · 156.4x5y range 1.6x – 220.7x

Currently above its 20-quarter median.

P/B · 9.0x5y range 1.2x – 16.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.92B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $18.67M
Q. Revenue: $5.84M
TTM EBITDA: $-185.61M
TTM Op. Income: $-200.08M
Q. Op. Income: $-52.20M
TTM Net Income: $-252.21M
Q. Net Income: $-81.06M
EPS: $-1.22
Shares Out.: $66.24M

$18.67M in TTM revenue grew 30.2% YoY, reaching $5.84M last quarter. TTM EBITDA of $-185.61M and TTM operating income of $-200.08M show growth is flowing through to the bottom line. However, net income is negative at $252.21M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -809.7%
Op. Margin: -893.7%
Net Margin: -1387.8%

Op. margin of -893.7% is down 60.1% YoY — costs are rising relative to revenue. Net margin at -1387.8% Over the past year, operating margin is down 7% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 156.4x
P/B Ratio: 9.0x

P/S of 156.4x and P/B of 9.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $985.10M
Cash: $413.03M
Long-Term Debt: $50.15M
Book Value: $324.05M
D/E Ratio: 0.2
Debt/EBITDA: N/A

With $985.10M in assets and $50.15M in long-term debt, D/E is 0.2and book value is $324.05M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 90% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-28.58M
TTM Free Cash Flow: $-161.45M
FCF Margin: -864.7%
FCF / Net Income: 0.6

TTM FCF of $-161.45M on $-28.58M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.